Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance
B Okopien, R Krysiak, ZS Herman - The Journal of Clinical …, 2006 - academic.oup.com
Context: Apart from lowering lipid levels, peroxisome proliferator-activated receptor (PPAR)
α activators (fibrates) produce many other favorable effects that may contribute to their …
α activators (fibrates) produce many other favorable effects that may contribute to their …
Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome
R Belfort, R Berria, J Cornell… - The Journal of Clinical …, 2010 - academic.oup.com
Context: Fenofibrate is a peroxisome proliferator-activated receptor α agonist widely used in
clinical practice, but its mechanism of action is incompletely understood. Objective: The aim …
clinical practice, but its mechanism of action is incompletely understood. Objective: The aim …
Metabolic and monocyte-suppressing actions of fenofibrate in patients with mixed dyslipidemia and early glucose metabolism disturbances
R Krysiak, A Stachura-Kułach, B Okopień - Pharmacological Reports, 2010 - Springer
The aim of this study was to compare the action of fenofibrate on monocyte cytokine release
between patients with isolated mixed dyslipidemia and dyslipidemia coexisting …
between patients with isolated mixed dyslipidemia and dyslipidemia coexisting …
Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and …
RS Rosenson, DA Wolff, AL Huskin… - Diabetes …, 2007 - Am Diabetes Assoc
OBJECTIVE—The aim of this study was to determine the effects of fenofibrate (160 mg/day)
on fasting and postprandial lipoproteins, oxidized fatty acids, and inflammatory mediators in …
on fasting and postprandial lipoproteins, oxidized fatty acids, and inflammatory mediators in …
Fenofibrate reduces fasting and postprandial inflammatory responses among hypertriglyceridemia patients with the metabolic syndrome
RS Rosenson, AL Huskin, DA Wolff, IB Helenowski… - Atherosclerosis, 2008 - Elsevier
OBJECTIVE: To examine the effects of fenofibrate (160mg/d) therapy on fasting and
postprandial cytokine production in subjects with metabolic syndrome and …
postprandial cytokine production in subjects with metabolic syndrome and …
Decrease in inflammatory cardiovascular risk markers in hyperlipidemic diabetic patients treated with fenofibrate
TJ Wu, HY Ou, CW Chou, SH Hsiao… - Annals of Clinical & …, 2007 - Assoc Clin Scientists
The goal was to investigate the effect of micronized fenofibrate, a hypolipidemic drug, on
inflammatory markers and proinsulin in patients with type 2 diabetes who had …
inflammatory markers and proinsulin in patients with type 2 diabetes who had …
Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia
M Pruski, R Krysiak, B Okopien - Diabetes care, 2009 - Am Diabetes Assoc
OBJECTIVE To compare the effect of short-term metformin and fenofibrate treatment,
administered alone or in sequence, on glucose and lipid metabolism, cardiovascular risk …
administered alone or in sequence, on glucose and lipid metabolism, cardiovascular risk …
Fenofibrate and metabolic syndrome
AT Kraja, MA Province, RJ Straka… - … Metabolic & Immune …, 2010 - ingentaconnect.com
The fibric acid derivative, fenofibrate (FF) has been used in the US since 1998 to manage
patients with dyslipidemia. Typical changes in serum lipids as a result of FF treatment …
patients with dyslipidemia. Typical changes in serum lipids as a result of FF treatment …
The Effect of Fenofibrate on the Levels of High Sensitivity C‐Reactive Protein in Dyslipidemic Obese Patients
E Coban, R Sari - Endocrine research, 2004 - Taylor & Francis
It is now well documented that obesity is associated with a chronic low‐grade inflammatory
state. Levels of high‐sensitivity C‐reactive protein, a marker of systemic inflammation and a …
state. Levels of high‐sensitivity C‐reactive protein, a marker of systemic inflammation and a …
Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial
IJ Jonkers, MF Mohrschladt, RG Westendorp… - The American journal of …, 2002 - Elsevier
PURPOSE: To determine whether hypertriglyceridemia is associated with systemic
inflammation, which may contribute to the increased cardiovascular risk in patients who …
inflammation, which may contribute to the increased cardiovascular risk in patients who …
相关搜索
- inflammation and hemostasis fenofibrate treatment
- hemostasis in patients markers of inflammation
- inflammation and hemostasis glucose tolerance
- glucose tolerance fenofibrate treatment
- glucose metabolism inflammation markers
- diabetic patients fenofibrate treatment
- pleiotropic action fenofibrate treatment
- favourable effects fenofibrate on lipids
- metabolism disturbances fenofibrate in patients
- lifestyle intervention fenofibrate treatment
- mixed dyslipidemia fenofibrate in patients
- hemostasis in patients fenofibrate treatment
- markers of inflammation fenofibrate treatment
- hemostasis in patients glucose tolerance
- markers of inflammation glucose tolerance
- favourable effects fenofibrate intervention